One case of refractory adenosarcoma of uterus

doi:10.3760/cma.j.issn.1007-1245.2024.03.031

International Medicine and Health Guidance News ›› 2024, Vol. 30 ›› Issue (3): 503-507.DOI: 10.3760/cma.j.issn.1007-1245.2024.03.031

• Case Report • Previous Articles Next Articles

One case of refractory adenosarcoma of uterus

Shi Juanjuan, Du Chao, Li Nan, Han Shanshan, Cui Xiujuan

Department of Gynecology, Tengzhou Central People's Hospital, Tengzhou 277599, China

Received:2023-08-10 Online:2024-02-01 Published:2024-03-07
Contact: Cui Xiujuan, Email: zhaoyi-2005@163.com
Supported by:
Shandong Medicine and Health Technology Project (202305010638);Practical Teaching Education Research Program of Jining Medical University in 2022 (JYSJ2022B49); Scientific Research Project of Sailing Plan of Tengzhou Central People's Hospital (202302);Zaozhuang Science and Technology Development Plan Project (2023NS38)

难治性子宫腺肉瘤1例

时娟娟杜超李南韩珊珊崔秀娟

济宁医学院附属滕州市中心人民医院妇科，滕州　277599

通讯作者: 崔秀娟，Email：zhaoyi_2005@163.com
基金资助:
山东省医药卫生科技项目（202305010638）；济宁医学院2022年度实践教学教育研究计划（JYSJ2022B49）；滕州市中心人民医院“扬帆”计划院级科研立项项目（202302）；枣庄市科技发展计划项目（2023NS38）

Abstract

Abstract:

Adenosarcoma of uterus is considered to be a low grade malignant uterine tumor. It has a low incidence and lacks specific clinical manifestations and laboratory and radiographic examinations. Most patients with adenosarcoma of uterus have good prognosis. This paper reports the diagnosis and treatment of a patient with refractory adenosarcoma of uterus who had metastasis rapidly and died after surgery, so as to improve the clinicians' understanding about this disease and take individualized treatment.

Key words:

Adenosarcoma of uterus, Metastasis, Prognosis, Death

摘要：

子宫腺肉瘤被认为低度恶性子宫肿瘤。子宫腺肉瘤发病率低，缺乏特异性临床表现及实验室和影像学检查，大部分子宫腺肉瘤患者预后较好。本文报道1例难治性子宫腺肉瘤患者术后迅速出现转移并致死亡的诊疗经过，以提高临床医师对该疾病的认识并作出个性化处理。

关键词:

子宫腺肉瘤, 转移, 预后, 死亡

Shi Juanjuan, Du Chao, Li Nan, Han Shanshan, Cui Xiujuan.

One case of refractory adenosarcoma of uterus [J]. International Medicine and Health Guidance News, 2024, 30(3): 503-507.

时娟娟杜超李南韩珊珊崔秀娟.

难治性子宫腺肉瘤1例 [J]. 国际医药卫生导报, 2024, 30(3): 503-507.

References

[1] 梁金晓,林仲秋.«FIGO2018癌症报告»——子宫肉瘤诊治指南解读[J].中国实用妇科与产科杂志,2018,34(12):1366-1371.DOI:10.19538/j.fk2018120116.
[2] Hodgson A, Amemiya Y, Seth A, et al. High-grade müllerian adenosarcoma: genomic and clinicopathologic characterization of a distinct neoplasm with prevalent TP53 pathway alterations and aggressive behavior[J]. Am J Surg Pathol, 2017,41(11):1513-1522. DOI: 10.1097/PAS.0000000000000907.
[3] Nathenson MJ, Conley AP. Prognostic factors for uterine adenosarcoma: a review[J]. Expert Rev Anticancer Ther, 2018,18(11):1093-1100. DOI: 10.1080/14737140.2018. 1518136.
[4] Ulrich UA, Denschlag D. Uterine adenosarcoma[J]. Oncol Res Treat, 2018,41(11):693-696. DOI: 10.1159/000494067.
[5] Ghartimagar D, Shrestha B, Ghosh A, et al. Adenosarcoma of uterus- rare biphasic malignant tumor: a case report[J]. JNMA J Nepal Med Assoc, 2021,59(234):200-203. DOI: 10.31729/jnma.5373.
[6] Zhang Y, Li Y, Huang H, et al. Low-grade endometrial stromal sarcoma and uterine adenosarcoma: a comparison of clinical manifestations and outcomes[J]. J Cancer, 2019,10(15):3352-3360. DOI: 10.7150/jca.30691.
[7] 陈思蕾,王光伟,赵万成,等.子宫肉瘤的术前诊断[J].国际生殖健康/计划生育杂志,2019,38(3):257-260.DOI:10.3969/j.issn.1674-1889.2019.03.019.
[8] Wais M, Tepperman E, Bernardini MQ, et al. A multicentre retrospective review of clinical characteristics of uterine sarcoma[J]. J Obstet Gynaecol Can, 2017,39(8):652-658. DOI: 10.1016/j.jogc.2017.03.090.
[9] Mallmann P. Uterine sarcoma - difficult to diagnose, hard to treat[J]. Oncol Res Treat, 2018,41(11):674. DOI: 10.1159/000494393.
[10] Dossi R, Frapolli R, Di Giandomenico S, et al. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1[J]. Int J Cancer, 2015,136(3):721-729. DOI: 10.1002/ijc.29023.
[11] Nagai T, Takai Y, Akahori T, et al. Novel uterine sarcoma preoperative diagnosis score predicts the need for surgery in patients presenting with a uterine mass[J]. Springerplus, 2014,3:678. DOI: 10.1186/2193-1801-3-678.
[12] Visnovsky J, Kudela E, Slavik P, et al. Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II[J]. Neuro Endocrinol Lett, 2015,36(8):750-757.
[13] Song KJ, Yu XN, Lv T, et al. Expression and prognostic value of lactate dehydrogenase-A and -D subunits in human uterine myoma and uterine sarcoma[J]. Medicine (Baltimore), 2018,97(14):e0268. DOI: 10.1097/MD.0000000000010268.
[14] Shah SH, Jagannathan JP, Krajewski K, et al. Uterine sarcomas: then and now[J]. AJR Am J Roentgenol, 2012,199(1):213-223. DOI: 10.2214/AJR.11.7287.
[15] Nathenson MJ, Ravi V, Fleming N, et al. Uterine adenosarcoma: a review[J]. Curr Oncol Rep, 2016,18(11):68. DOI: 10.1007/s11912-016-0552-7.
[16] 谢玲玲,林荣春,林仲秋.«2021 NCCN子宫肿瘤临床实践指南(第1版)»解读[J].中国实用妇科与产科杂志,2021,37(1):75-81.DOI:10.19538/j.fk2021010119.
[17] Nathenson MJ, Conley AP, Lin H, et al. The importance of lymphovascular invasion in uterine adenosarcomas: analysis of clinical, prognostic, and treatment outcomes[J]. Int J Gynecol Cancer, 2018,28(7):1297-1310. DOI: 10.1097/IGC.0000000000001306.
[18] Machida H, Nathenson MJ, Takiuchi T, et al. Significance of lymph node metastasis on survival of women with uterine adenosarcoma[J]. Gynecol Oncol, 2017,144(3):524-530. DOI: 10.1016/j.ygyno.2017.01.012.
[19] Denschlag D, Thiel FC, Ackermann S, et al. Sarcoma of the uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015) [J]. Geburtshilfe Frauenheilkd, 2015,75(10):1028-1042. DOI: 10.1055/s-0035-1558120.
[20] Agarwal R, Rajanbabu A, Nair IR, et al. Endometrial stromal sarcoma-a retropsective analysis of factors affecting recurrence[J]. Eur J Obstet Gynecol Reprod Biol, 2017,216:92-97. DOI: 10.1016/j.ejogrb.2017.07.011.
[21] Si M, Jia L, Song K, et al. Role of lymphadenectomy for uterine sarcoma: a meta-analysis[J]. Int J Gynecol Cancer, 2017,27(1):109-116. DOI: 10.1097/IGC.0000000000000842.
[22] Hu H, Wei Z, Zhao H, et al. Epidemiology of adenosarcoma and the inverse probability of treatment weighting (IPTW) adjusted survival analysis of lymph node dissection in uterine adenosarcoma[J]. Medicine (Baltimore), 2022,101(38):e30607. DOI: 10.1097/MD.0000000000030607.
[23] Nathenson MJ, Conley AP, Lin H, et al. Treatment of recurrent or metastatic uterine adenosarcoma[J]. Sarcoma, 2017,2017:4680273. DOI: 10.1155/2017/4680273.
[24] Carroll A, Ramirez PT, Westin SN, et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence[J]. Gynecol Oncol, 2014,135(3):455-461. DOI: 10.1016/j.ygyno.2014.10.022.
[25] Yuan Z, Shen K, Yang J, et al. Uterine adenosarcoma: a retrospective 12-year single-center study[J]. Front Oncol, 2019,9:237. DOI: 10.3389/fonc.2019.00237.
[26] Tate K, Watanabe R, Yoshida H, et al. Uterine adenosarcoma in Japan: clinicopathologic features, diagnosis and management[J]. Asia Pac J Clin Oncol, 2018,14(4):318-325. DOI: 10.1111/ajco.12859.
[27] Yuan Z, Cao D, Yu M, et al. Uterine and cervical adenosarcoma: a retrospective study of overall oncologic outcomes and fertility preservation in early-stage disease[J]. Oncologist, 2019,24(9):e870-e879. DOI: 10.1634/theoncologist.2018-0791.
[28] Plentz TBSF, Candido EC, Dias LF, et al. Diagnosis, treatment and survival of uterine sarcoma: a retrospective cohort study of 122 cases[J]. Mol Clin Oncol, 2020,13(6):81. DOI: 10.3892/mco.2020.2151.

One case of refractory adenosarcoma of uterus

难治性子宫腺肉瘤1例

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	Yu Xiaojie, Cheng Lihao, Zhang Hao, Zhang Haojie, Yang Zhenlin. Research progress on relationship between iron death and chemotherapy resistance in patients with breast cancer [J]. International Medicine and Health Guidance News, 2024, 30(3): 353-356.
[2]	Liu Ming, Liu Shuai, Zhang Nan. Research progress of exemption from radiotherapy after breast-conserving surgery in patients with early-stage breast cancer [J]. International Medicine and Health Guidance News, 2024, 30(3): 357-362.
[3]	Cui Yuxia, Du Bing, Gao Fengshuang. Effect of self-care mode under framework of chronic disease trajectory for elderly patients with gastric carcinoma undergoing gastrectomy [J]. International Medicine and Health Guidance News, 2024, 30(3): 524-528.
[4]	Luo Xiaojie, Wang Weiwei, Wang Yimeng, Wang Yu. Noninvasive prediction of 28-day mortality in patients with sepsis associated acute respiratory distress syndrome [J]. International Medicine and Health Guidance News, 2024, 30(2): 263-268.
[5]	Wang Xinyin. Effect of sodium nitroprusside on clinical signs and prognosis of hypertensive crisis patients [J]. International Medicine and Health Guidance News, 2024, 30(2): 284-288.
[6]	Jiang Junxuan, Fang Yuan. Application value of Buzhong Yiqi decoction in immunotherapy of NSCLC with negative driver gene [J]. International Medicine and Health Guidance News, 2024, 30(2): 305-309.
[7]	Feng Nankai. Ultrasound-guided local comprehensive intervention therapy for patients with large liver cancer [J]. International Medicine and Health Guidance News, 2024, 30(1): 62-66.
[8]	Zhan Zeyu, Lin Sien, Wei Bo. Research progress on clinical treatment and innovative therapy of osteosarcoma [J]. International Medicine and Health Guidance News, 2023, 29(9): 1197-1200..
[9]	Hou Changran, Jiang Jingru, Hua Yitong. Progress of chondroitin polymerization factor in breast cancer [J]. International Medicine and Health Guidance News, 2023, 29(9): 1201-1204.
[10]	Zhang Qi, Zhao Yanchao. Effect of omeprazole injection combined with enteral nutrition support on patients with acute pancreatitis [J]. International Medicine and Health Guidance News, 2023, 29(7): 978-982.
[11]	Yuan Fawei, Li Bingqi. Effect and prognosis of extracorporeal membrane oxygenation in the treatment of respiratory failure [J]. International Medicine and Health Guidance News, 2023, 29(7): 973-977.
[12]	Wu Shaohui, Xiao Yingxiu, Yang Danxiao, Peng Haicong, Huang Xiaoxin. Effects of homocysteine and cystatin C on efficacy of intravenous thrombolysis for patients with acute ischemic stroke [J]. International Medicine and Health Guidance News, 2023, 29(6): 813-817.
[13]	Zhang Xiumei, Liu Pengtao. A case of solitary extracranial rib metastasis after operation for benign meningioma [J]. International Medicine and Health Guidance News, 2023, 29(6): 839-841.
[14]	Li Feng, Su Yiwei, Wang Zhi. Analysis of prognostic factors in patients with acute paraquat poisoning [J]. International Medicine and Health Guidance News, 2023, 29(5): 632-637.
[15]	Chen Ranran, Gao Xiaojie, Jia Shilei, Liang Die. Clinical characteristics and risk factors of acute kidney injury in children with nephrotic syndrome [J]. International Medicine and Health Guidance News, 2023, 29(5): 675-679.